论文部分内容阅读
目的探讨米力农治疗婴幼儿重症肺炎合并心力衰竭的临床疗效分析。方法选取2016年10月至2017年7月于我院进行治疗的重症肺炎合并心力衰竭患儿共82例作为本次研究对象。依照就诊时间不同将82例患儿随机分为两组进行探讨,对照组和观察组各41例,对照组患儿在常规治疗的基础上加用多巴胺治疗,观察组患儿在常规治疗的基础上增加使用米力农治疗,比较疗效。结果观察组患儿治疗优良率显著优于对照组,治疗过程中患儿发生不良反应的概率也低于对照组,组间数据差异有统计学意义(P<0.05)。结论常规治疗的基础上增加使用米力农治疗重症肺炎合并心力衰竭患儿疗效显著,不良反应率低,具有较高的安全性。
Objective To investigate the clinical efficacy of Milrinone in the treatment of infantile severe pneumonia complicated with heart failure. Methods A total of 82 children with severe pneumonia complicated with heart failure who were treated in our hospital from October 2016 to July 2017 were selected as the study objects. According to different treatment time, 82 cases of children were randomly divided into two groups to explore the control group and the observation group of 41 cases, the control group of children on the basis of conventional treatment with dopamine treatment, observation group of children in the conventional treatment based Increased use of Milrinone treatment, more effective. Results The excellent and good rate of treatment in observation group was significantly better than that in control group, and the incidence of adverse reactions in children during treatment was also lower than that in control group. The difference between the two groups was statistically significant (P <0.05). Conclusion The conventional treatment based on the increased use of milrinone treatment of severe pneumonia complicated with heart failure in children with significant effect, low adverse reaction rate, with high safety.